| | | Advertisement |  | | | | | | | Advertisement | | | | | | |
Advertisement | | Searching for a new career?
At Nature Research we frequently recruit talented individuals to join our editorial and publishing teams. If you have a PhD and a passion for science this may be the perfect career for you.
Visit our research editorial and publishing careers website to discover more about what we do |  | | | | | | Comment | |  |  | | | Glimmers in illuminating the druggable genome pp301 - 302
Griffin Rodgers, Christopher Austin, James Anderson, Aaron Pawlyk, Christine Colvis, Ronald Margolis & Jenna Baker
doi:10.1038/nrd.2017.252
Much biomedical research continues to focus on a small proportion of the human genome that has already been studied intensively. The Illuminating the Druggable Genome programme, initiated as a pilot project by the US National Institutes of Health Common Fund in 2014, is now being implemented to accelerate the investigation of subsets of understudied proteins that have potential therapeutic relevance. | | News and Analysis | | | | | | Microglia-targeted candidates push the Alzheimer drug envelope pp303 - 305
Asher Mullard
doi:10.1038/nrd.2018.65
Denali Therapeutics is taking a swing at neuroinflammation with a first-in-man trial of a RIPK1 inhibitor, while the company and others search for ways to target microglial biology more precisely. | | | | | Industry embraces virtual trial platforms pp305 - 306
Elie Dolgin
doi:10.1038/nrd.2018.66
Site-less trials promise to speed up drug development — but obstacles to in-home data collection abound. | | | | News in Brief | | | | | IDO takes a blow p307
Asher Mullard
doi:10.1038/nrd.2018.67 | | | | | Novartis grows its gene therapy ambitions p307
Asher Mullard
doi:10.1038/nrd.2018.68 | | | | | Cashing in with off-the-shelf CAR Ts p307
Asher Mullard
doi:10.1038/nrd.2018.69 | | | | Biobusiness Briefs | | | | | Regulatory watch: FDA new drug approvals in Q1 2018 p309
Lisa Urquhart
doi:10.1038/nrd.2018.61 | | | | An Audience With | | | | | Anja König p310
doi:10.1038/nrd.2018.60
Anja König, Global Head of the Novartis Venture Fund, discusses the changing corporate venture capital landscape. | | | | From the analyst's couch | | | | | The gastroesophageal cancer drug market pp311 - 312
Paul Wilcock & Rachel M. Webster
doi:10.1038/nrd.2018.35
Immune checkpoint inhibitors are forecast to expand the market for gastroesophageal cancer drugs, which is particularly large in Asia. | | | Advertisement | | | Nature Roundtable: The Future of Medicine, 16 July, 2018 | Darmstadt, Germany In association with the Curious2018 - Future Insight Conference, Nature and Nature Medicine have invited outstanding researchers in academia and industry for a round table discussion of the most exciting scientific developments that are shaping the future of medicine. Discover more and apply for your free ticket. |  | | | | | | Research Highlights | | | | | | Advertisement | | Nature Outlook: The future of medicine
Modern medicine is affording people longer and healthier lives. But researchers want to take improvements in health even further. With advances in gene editing, technology to overcome paralysis and efforts to address high drug costs, the future of medicine is bright.
Get your free access >>
Produced with support from:
Merck KGaA, Darmstadt, Germany | | | | | | |  | Analysis | | | | | | Unexplored therapeutic opportunities in the human genome pp317 - 332
Tudor I. Oprea, Cristian G. Bologa, Søren Brunak, Allen Campbell, Gregory N. Gan, Anna Gaulton, Shawn M. Gomez, Rajarshi Guha, Anne Hersey, Jayme Holmes, Ajit Jadhav, Lars Juhl Jensen, Gary L. Johnson, Anneli Karlson, Andrew R. Leach, Avi Ma'ayan, Anna Malovannaya, Subramani Mani, Stephen L. Mathias, Michael T. McManus, Terrence F. Meehan, Christian von Mering, Daniel Muthas, Dac-Trung Nguyen, John P. Overington, George Papadatos, Jun Qin, Christian Reich, Bryan L. Roth, Stephan C. Schürer, Anton Simeonov, Larry A. Sklar, Noel Southall, Susumu Tomita, Ilinca Tudose, Oleg Ursu, Dušica Vidović, Anna Waller, David Westergaard, Jeremy J. Yang & Gergely Zahoránszky-Köhalmi
doi:10.1038/nrd.2018.14
In 2014, the Illuminating the Druggable Genome programme was launched to promote the exploration of currently understudied but potentially druggable proteins. This article discusses how the systematic collection and processing of a wide array of biological and chemical data as part of this programme has enabled the development of evidence-based criteria for tracking the target development level of human proteins, which indicates a substantial knowledge deficit for approximately one out of three proteins in the human proteome. It also highlights the nature of the unexplored therapeutic opportunities for major protein families. | | Reviews | | | | | | Chemical probes and drug leads from advances in synthetic planning and methodology pp333 - 352
Christopher J. Gerry & Stuart L. Schreiber
doi:10.1038/nrd.2018.53
Strategies such as diversity-oriented synthesis aim to explore novel areas of chemical space efficiently by populating small-molecule screening libraries with compounds containing structural features that are typically under-represented in commercially available screening collections. This article highlights how the design and synthesis of such libraries have been enabled by modern synthetic chemistry and illustrates the impact of the resultant chemical probes and drug leads in a wide range of diseases. | | | | | Kinase inhibitors: the road ahead pp353 - 377
Fleur M. Ferguson & Nathanael S. Gray
doi:10.1038/nrd.2018.21
Existing kinase inhibitor drugs predominantly target receptor tyrosine kinases in cancer. Here, Gray and Ferguson review novel kinase targets in oncology, degenerative diseases, inflammatory disorders and infectious diseases. Advances in medicinal chemistry, selectivity profiling and computer-aided drug design, which are enabling the design of improved kinase inhibitors, are discussed. | | Correspondence | | | | | | Senotherapeutics for healthy ageing p377
Laura J. Niedernhofer & Paul D. Robbins
doi:10.1038/nrd.2018.44 | | Corrigenda | | | | | | Unexplored therapeutic opportunities in the human genome p377
Tudor I. Oprea, Cristian G. Bologa, Søren Brunak, Allen Campbell, Gregory N. Gan, Anna Gaulton, Shawn M. Gomez, Rajarshi Guha, Anne Hersey, Jayme Holmes, Ajit Jadhav, Lars Juhl Jensen, Gary L. Johnson, Anneli Karlson, Andrew R. Leach, Avi Ma'ayan, Anna Malovannaya, Subramani Mani, Stephen L. Mathias, Michael T. McManus, Terrence F. Meehan, Christian von Mering, Daniel Muthas, Dac-Trung Nguyen, John P. Overington, George Papadatos, Jun Qin, Christian Reich, Bryan L. Roth, Stephan C. Schürer, Anton Simeonov, Larry A. Sklar, Noel Southall, Susumu Tomita, Ilinca Tudose, Oleg Ursu, Dušica Vidović, Anna Waller, David Westergaard, Jeremy J. Yang & Gergely Zahoránszky-Köhalmi
doi:10.1038/nrd.2018.52 | | | | | Accelerating the development of therapeutic strategies for drug-resistant tuberculosis p377
Michael J. Vjecha, Simon Tiberi & Alimuddin Zumla
doi:10.1038/nrd.2018.64 | | | Advertisement | | nature.com webcasts
Nature Research Custom presents a webcast on: Ultra-sensitive detection of interferon alpha protein in human disease by digital ELISA
Date: Tuesday, May 15, 2018
Darragh Duffy, Institut Pasteur, will address how digital ELISA enables direct qualification of IFNa protein in human samples. This webcast has been produced on behalf of the sponsor who retains sole responsibility for content
Register for FREE
Sponsored by: Quanterix | | | | | | | | | | | | Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com | | | | | | | | |
No comments:
Post a Comment